Research
Where Next for Lp(a)?
JAMA ·
The Brief
- The Lp(a)HORIZON trial reported top-line results on lipoprotein(a) lowering and major adverse cardiovascular events.
- JAMA Medical News covers the trial results and asks what comes next for Lp(a)-focused research and treatment.
- The source is a single JAMA Current Issue article; no further trial details are provided in the sources.
Why it matters
Lp(a) is a genetically determined cardiovascular risk factor, and results from a large outcomes trial show whether lowering it reduces cardiovascular events, which bears on how science readers interpret future Lp(a) research.
Who’s affected
- cardiologists and lipidologists
- researchers studying cardiovascular disease prevention
- #lipoprotein(a)
- #cardiovascular
- #clinical trial
- #lipids
- #heart disease
This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.
Timeline
JAMA Current Issue publishes Medical News article 'Where Next for Lp(a)?' on Lp(a)HORIZON top-line results
JAMA Current Issue
Where Next for Lp(a)?